In re Bystolic Antitrust Litig., No. 20-cv-05735 (S.D.N.Y)
In the Bystolic case, Faruqi & Faruqi represents a proposed class of direct purchasers of Forest Laboratories’ (now AbbVie) blood pressure drug, Bystolic. The complaint alleges that Forest entered into reverse payment agreements with several would-be generic competitors to delay market entry of their generic Bystolic products.
If you have information regarding this case that you would like to make available, please click here to contact us about our investigation.
1617 JFK Boulevard, Suite 1550
19103 Philadelphia, Pennsylvania
Joseph T. Lukensjlukens@faruqilaw.comPhone (215) 277-5770Fax (215) 277-5771
Peter Kohnpkohn@faruqilaw.comPhone (215) 277-5770Fax (215) 277-5771
Our offices are nationwide. If you have any questions about a case or our firm, please contact us.
685 Third Avenue 26th Floor New York, New York10017 (212) 983-9330 (877) 247-4292 (212) 983-9331
10866 Wilshire Boulevard Suite 1470 Los Angeles, California90024 (424) 256-2884 (424) 256-2885
3975 Roswell Rd Suite A Atlanta, Georgia30342 (404) 847-0617 (404) 506-9534